Nyrada Inc – Nyrada Commences Walter Reed Traumatic Brain Injury Study
Highlights: •Walter Reed Army Institute of Research study of NYR-BI03 in traumatic brain injury has commenced and is expected to… Read more
Highlights: •Walter Reed Army Institute of Research study of NYR-BI03 in traumatic brain injury has commenced and is expected to… Read more
April 2024 Investor Presentation
Highlights: • Lead Brain Injury Program drug candidate NYR-BI03 demonstrated strong efficacy: – rescued average 42% of the brain injury… Read more
Highlights: •NYR-BI03 Good Laboratory Practice (GLP) safety testing studies have commenced and are expected to conclude in 2HCY2024. •First in-human… Read more
Highlights: •Nyrada has successfully raised $1.755 million of new equity capital (before costs). •Nyrada Directors will subscribe for an additional… Read more
Highlights: •Nyrada’s lead Brain Injury Program drug candidate NYR-BI03 demonstrated strong efficacy in reducing injury in a preclinical study. •NYR-BI03… Read more
Nyrada Inc (ASX: NYR), a drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases,… Read more
New brain injury drug candidate NYR-BI03 to be advanced instead of NYR-BI02 due to demonstrated superior potency and safety profile,… Read more
• All required preclinical safety and toxicology studies have been completed, supporting advancement to a first-in-human clinical trial • Submission… Read more